Advertisement

Picture EBD Group Partnering Events Spring 2018 CBPF18 BES18 BEE18 600x060px
Document › Details

Helsinn Healthcare S.A.. (1/30/18). "Press Release: Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement". Lugano.

Region Region Monaco
Organisations Organisation Helsinn International Services S.a.r.l.
  Group Helsinn (Group)
  Organisation 2 Scientific Centre of Monaco (CSM, Centre Scientifique de Monaco)
Products Product cancer drug
  Product 2 drug discovery
Index term Index term Helsinn–Scientific Centre of Monaco: cancer drug, 201801– collab research new pharmacological inhibitors for clear cell renal cell carcinoma
Person Person Braglia, Riccardo (Helsinn Healthcare 200602 Managing Director)
     


Investigating the role of pharmacological inhibitors in kidney cancer


Helsinn International Services, Sarl, a Monaco-based affiliate of the Swiss Pharmaceutical Group focused on building quality cancer care products, and the Scientific Centre of Monaco (CSM), today announce that they have signed a collaboration agreement to support a research project aimed at developing pharmacological inhibitors for the most common form of kidney cancer: clear cell renal cell carcinoma (ccRCC).

ccRCC is diagnosed in over 200,000 patients worldwide each year and the number of people affected continues to increase. The current five year survival rate for stage IV patients is only 10 to 20%. While the treatment for ccRCC over the past decade has shifted from an immunologic to an anti-angiogenic or targeted therapy approach, the kidney disease remains incurable when metastatic.

Studies investigating neuropilins (NRP) reveal that they are over-expressed in several tumors. However, their inhibition is currently poorly exploited in oncology. This observation provided the rationale for further research into the potential of NRP inhibitors for the treatment of ccRCC. Conducted by PhD candidate Aurore Dumond, under the supervision of Dr Renaud Grépin and Dr Gilles Pagès, the research project is: “Targeting Neuropilin-1 (NRP1) and Neuropilin-2 (NRP-2) and their respective ligands, Vascular Endothelial Growth Factor A (VEGF-A) and Vascular Endothelial Growth Factor-C (VEGF-C) in ccRCC.

Under the terms of the agreement, Helsinn is sponsoring Ms. Dumond’s doctoral thesis dissertation over the next three years.

“We are very pleased to have entered into this partnership with Helsinn as it allows us to pursue a novel area of research in what is an increasingly prevalent form of cancer worldwide”, said Professor Rampal, President of the CSM.

Riccardo Braglia, Helsinn Group Vice Chairman and CEO added, “The Principality of Monaco is becoming a hub for technological innovation, including in the life sciences and we are pleased to be supporting this type of project from this region. Clear cell renal cell carcinoma is the most common form of kidney cancer and we are excited by the prospects of this program and the benefit it could yield for patients.”


About the Helsinn Group

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, the U.S., Monaco and China, as well as a product presence in approximately 190 countries globally.


About the Scientific Centre of Monaco

The Scientific Centre of Monaco (CSM) was founded in 1960 at the request of Prince Rainier III, Prince of Monaco, to be the Scientific Research Agency of the Principality of Monaco. It initially only conducted research in Marine Biology. Upon his accession to the throne in 2005, Prince Albert II expressed the wish to develop the Institution as a result of which two new research departments were added: Bio-Medicine and Polar Biology. Supported by the Monaco Government, the CSM has scientific partnerships with various International Universities, Research Institutes and International Organisations. It is also a collaborating center of the World Health Organisation.


For more information:

Helsinn Group Media Contact:
Paola Bonvicini
Group Head of Communication
Lugano, Switzerland
Tel: +41 (0) 91 985 21 21
Info-hhc@helsinn.com

For more information, please visit www.helsinn.com and follow us on Twitter, LinkedIn and Vimeo.

Centre Scientifique de Monaco:
8 Quai Antoine Ier
MC 98000 MONACO
Présidence et Secrétariat général
Tel. +377 98 98 86 60
centre@centrescientifique.mc

For more information, please visit www.centrescientifique.mc

   
Record changed: 2018-02-08

Advertisement

Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 600x60px

More documents for Helsinn (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Partnering Events Spring 2018 CBPF18 BES18 BEE18 600x060px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group Partnering Events Spring 2018 CBPF18 BES18 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture EBD Group BIO-Europe Spring 2018 BES Amsterdam March 120x180px